CDKN2A and head and neck squamous cell carcinoma: However, as a significant proportion of CDKN2A/CDKN2B alterations are due to gene inactivation by promoter and gene methylation, their gene reactivation by the use of small molecules targeting the epigenetic machinery, including histone and DNA methylases and acetylases, could represent an attractive HNSCC management strategy [70].